The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Jazz Pharmaceuticals missed slightly on revenues and beat slightly on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share dropped significantly.
Margins dropped across the board.
Jazz Pharmaceuticals reported revenue of $175.5 million. The nine analysts polled by S&P Capital IQ anticipated sales of $178.8 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $73.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.34. The 10 earnings estimates compiled by S&P Capital IQ forecast $1.31 per share. GAAP EPS of $0.55 for Q3 were 20% lower than the prior-year quarter's $0.69 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 81.4%, 1,330 basis points worse than the prior-year quarter. Operating margin was 31.5%, 2,270 basis points worse than the prior-year quarter. Net margin was 18.9%, 2,540 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $195.8 million. On the bottom line, the average EPS estimate is $1.47.
Next year's average estimate for revenue is $611.4 million. The average EPS estimate is $4.77.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 208 members out of 274 rating the stock outperform, and 66 members rating it underperform. Among 72 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give Jazz Pharmaceuticals a green thumbs-up, and 22 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals is buy, with an average price target of $67.38.
- Add Jazz Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.